Sotera Health Co (SHC) Stock Forecast & Price Target
Sotera Health Co · NASDAQ
$18.60-0.30 (-1.59%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Sotera Health Co, 7 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $18.00 to $25.00, so the covering firms are broadly aligned. The average target of $21.86 sits 18% above the current $18.60. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.28 next quarter toward $1.07 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Strong Buy
Strong Buy00%
Buy788%
Hold113%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Sotera Health Co.
As of Sep, 7 of 8 firms rate SHC a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SHC EPS & revenue forecast
EPS · NEXT QUARTER
$0.28
Range $0.27 – $0.28 · 10 analysts · +6% YoY
Next period, 10 analysts expect Sotera Health Co to earn $0.28 a share (range $0.27 – $0.28), versus $0.26 a year earlier. Full-year consensus is $0.98, growing to $1.07 the year after.
REVENUE · NEXT QUARTER
$325.6M
Range $323.0M – $328.8M · 10 analysts · +7% YoY
Revenue is expected to reach $325.6M (range $323.0M – $328.8M), +7.3% year-over-year. Full-year consensus is $1.2B, rising to $1.3B next year.
Top analysts covering Sotera Health Co
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SHC.
#1
Luke Sergott
Barclays · Rank #246
Buy
$22.00+18.3% to target
Overall win rate
40%
+ Follow
#2
Matthew Sykes
Goldman Sachs · Rank #274
Buy
$17.00-8.6% to target
Overall win rate
38%
+ Follow
#3
Jason Bednar
Piper Sandler · Rank #276
Buy
$25.00+34.4% to target
Overall win rate
35%
+ Follow
#4
Patrick Donnelly
Citigroup · Rank #344
Buy
$23.00+23.7% to target
Overall win rate
30%
+ Follow
#5
CW
Casey Woodring
JP Morgan
Hold
$18.00-3.2% to target
Coverage
—
+ Follow
SHC stock forecast FAQ
What is SHC's average 12-month price target?+
The 7 analysts with a live target average $21.86 for Sotera Health Co over the next 12 months, ranging from a $25.00 high to a $18.00 low.
Is SHC stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 8 analyst ratings, 7 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SHC?+
The Street-high target is $25.00 (Citigroup), and the Street-low is $18.00 (JP Morgan). The average of all 7 active targets is $21.86.
How many Wall Street analysts cover SHC?+
8 analysts have an active rating on Sotera Health Co, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering SHC?+
Among analysts who currently cover SHC, Luke Sergott of Barclays has the strongest overall Quantellect track record (Rank #246). Their current call is Buy with a $22.00 target.
What is Sotera Health Co's projected EPS for next quarter?+
The consensus estimate is $0.28 per share (range $0.27 – $0.28) across 10 analysts. Full-year EPS is projected at $0.98, rising to $1.07 the following year.
How much revenue is Sotera Health Co expected to report next quarter?+
Consensus revenue is $325.6M (range $323.0M – $328.8M). Full-year revenue is projected at $1.2B, growing to $1.3B next year.
Have analysts been upgrading or downgrading SHC lately?+
As of Sep, 7 of 8 firms rate SHC a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SHC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Citigroup
